Legend Biotech: Carvykti Makes Billions, But The Profits Are ElusiveSeeking Alpha · 2 days ago
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T TherapyGlobeNewsWire · Oct 15, 2026
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple MyelomaGlobeNewsWire · Oct 1, 2026
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Consensus Price Target of $53.14 According to AnalystsDefense World · Sep 26, 2026
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single InfusionGlobeNewsWire · Sep 25, 2026
Legend Biotech taps Novartis veteran Zhang as CEOReuters · Sep 15, 2026Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | $0.12 | $0.09 | Miss |
| May 12, 2026 | -$0.02 | -$0.15 | Miss |
| Mar 10, 2026 | -$0.17 | -$0.08 | Beat |
| Nov 12, 2025 | -$0.13 | -$0.11 | Beat |
| Aug 11, 2025 | -$0.11 | -$0.34 | Miss |
| May 13, 2025 | -$0.23 | -$0.07 | Beat |